** Shares of drugmaker Invivyd IVVD.O fall 37.2% to $1.11 premarket
** Co says the U.S. FDA has declined to expand the emergency use authorization of its COVID-19 prevention drug
** The expansion was to include those whose immunity is impaired by certain conditions such as cancer and organ transplant, and for whom alternative options are not accessible or appropriate
** The drug Pemgarda is already authorized for emergency use in those with compromised immunity due to a medical condition or receiving medicines that suppress the immune system, and unlikely to have an adequate response to vaccination
** IVVD fell 88.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.